Editorial 3rd Intercontinental Cooperative ITP Study Group (ICIS) Expert Meeting in Basel, Switzerland, September 2009

Kühne, Thomas; Imbach, Paul; Kühne, Thomas
July 2010
Annals of Hematology;Jul2010, Vol. 89, p1
Academic Journal
journal article
The article presents information on the 3rd Intercontinental Cooperative Immune Thrombocytopenia (ITP) Study Group (ICIS) Expert Meeting, held during September 3-5, 2009, in Basel, Switzerland. The event was attended by more than 100 experts involved in basic science and clinical research. They discussed the issues related to ITP including disease management and future research.


Related Articles

  • Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia. Tamary, Hannah; Roganovic, Jelena; Chitlur, Meera; Nugent, Diane; Nugent, Diane J // Annals of Hematology;Jul2010, Vol. 89, p5 

    The rarity of severe complications of this disease in children makes randomized clinical trials in immune thrombocytopenia (ITP) unfeasible. Therefore, the current management recommendations for ITP are largely dependent on clinical expertise and observations. As part of its discussions during...

  • Hidden maternal autoimmune thrombocytopenia complicated by fetal subdural hematoma-case report and review of the literature. Rios, Lívia; Araujo Júnior, Edward; Nardozza, Luciano; Haratz, Karina; Moron, Antonio; Martins, Marília // Child's Nervous System;Jul2012, Vol. 28 Issue 7, p1113 

    The article presents case study of having subdural hematoma related to fetal autoimmune thrombocytopenia. It has been informed that a 35-year-old primigravida was referred for routine scan at 34 gestational weeks (GW) and a full-term boy was delivered by cesarean section at 39 GW with a...

  • Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjögren's syndrome. Choung, Bum-Su; Yoo, Wan-Hee // Rheumatology International;May2012, Vol. 32 Issue 5, p1353 

    Sjogren's syndrome (SS) is a systemic autoimmune disease characterized by xerophthalmia, xerostomia and extraglandular manifestations. Anemia, leukopenia, thrombocytopenia and lymphoproliferative disorders, including lymphoma are well-known extraglandular, hematological complications of SS. We...

  • The Ratio of Treg/Th17 Cells Correlates with the Disease Activity of Primary Immune Thrombocytopenia. Lili Ji; Yanxia Zhan; Fanli Hua; Feng Li; Shanhua Zou; Weiguang Wang; Dongli Song; Zhihui Min; Hao Chen; Yunfeng Cheng // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Background: Primary immune thrombocytopenia (ITP) is an autoimmune heterogeneous disorder that is characterized by decreased platelet count. Regulatory T (Treg) cells and T helper type 17 (Th17) cells are two subtypes of CD4+ T helper (Th) cells. They play opposite roles in immune tolerance and...

  • Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature. Salama, A.; Rieke, M.; Kiesewetter, H.; Depka, M.; von Depka, M // Annals of Hematology;Jan2009, Vol. 88 Issue 1, p11 

    Patients with severe and refractory autoimmune thrombocytopenia (ITP) have significant morbidity and mortality rates. Currently, high-dose methylprednisolone and/or high-dose IVIgG are recommended for the emergency treatment of such patients with uncontrolled bleeding. However, some patients do...

  • Future research in ITP: an ICIS consensus. Zehnder, James L.; Semple, John W.; Imbach, Paul; Neufeld, Ellis J.; Buchanan, George R.; Cines, Douglas B.; ICIS Study Group on Future Research in ITP // Annals of Hematology;Jul2010, Vol. 89, p19 

    While much has been learned about the basic immunology and clinical characteristics of immune thrombocytopenia, many important questions remain with regard to pathogenesis, disease progression, identification of novel therapeutic targets and approaches, and clinical trials that rationalize and...

  • Evaluating bleeding severity in immune thrombocytopenia (ITP). Neunert, Cindy E. // Annals of Hematology;Jul2010, Vol. 89, p47 

    Despite immune thrombocytopenia (ITP) being one of the most common conditions encountered by the pediatric hematologist, relatively few prospective investigations of ITP exist, and treatment approaches remain highly variable. The ideal prospective clinical trial would use a reduction in severe...

  • Moving towards a new era in the management of chronic immune thrombocytopenia. Wadenvik, Hans; Olsson, Bob // Annals of Hematology;Jul2010, Vol. 89, p87 

    Immune thrombocytopenia (ITP) is an organ-specific autoimmune disease in which a low concentration of plasma thrombopoietin (TPO) contributes to the thrombocytopenia. Functional thrombopoietin deficiency in response to thrombocytopenia is central to the pathophysiology of chronic ITP. Decreased...

  • ICIS supplementum abstracts.  // Annals of Hematology;Jul2010, Vol. 89, p105 

    The article presents abstracts on immune thrombocytopenia (ITP) which include the use of Rituximab for treating children with severe refractory Immune thrombocytopenic purpura, secondary failure of treatment in Egyptian children and adolescents suffering with chronic ITP, and the effectiveness...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics